Volume | 17,598 |
|
|||||
News | - | ||||||
Day High | 5.46 | Low High |
|||||
Day Low | 5.15 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Aptorum Group Ltd | APM | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
5.45 | 5.15 | 5.46 | 5.48 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
306 | 17,598 | US$ 5.30 | US$ 93,257 | - | 1.35 - 17.49 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
11:33:20 | 100 | US$ 5.30 | USD |
Aptorum Group Ltd Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
21.98M | 4.17M | - | 1.3M | -9.8M | -2.35 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aptorum News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical APM Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 5.35 | 6.50 | 5.15 | 5.59 | 29,307 | -0.05 | -0.93% |
1 Month | 9.48 | 11.19 | 5.04 | 8.47 | 69,855 | -4.18 | -44.09% |
3 Months | 1.61 | 17.49 | 1.35 | 8.44 | 2,604,870 | 3.69 | 229.19% |
6 Months | 1.78 | 17.49 | 1.35 | 8.42 | 1,211,587 | 3.52 | 197.75% |
1 Year | 2.84 | 17.49 | 1.35 | 7.73 | 722,857 | 2.46 | 86.62% |
3 Years | 24.80 | 35.40 | 1.35 | 15.05 | 580,290 | -19.50 | -78.63% |
5 Years | 146.60 | 332.80 | 1.35 | 21.48 | 482,618 | -141.30 | -96.38% |
Aptorum Description
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. Its lead projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services. |